Literature DB >> 16151917

The ratio of alpha-galactosidase to beta-glucuronidase activities in dried blood for the identification of female Fabry disease patients.

Z Lukacs1, A Keil, A Kohlschütter, M Beck, E Mengel.   

Abstract

Female heterozygous patients with Fabry disease are difficult to identify because of the relatively high residual activity of alpha-galactosidase. We systematically evaluated the activities of various lysosomal enzymes in dried blood samples from Fabry patients and found that the beta-glucuronidase activity was frequently elevated. The ratio of alpha-galactosidase to beta-glucuronidase proved to be a helpful tool for the diagnosis of female Fabry disease patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16151917     DOI: 10.1007/s10545-005-0039-4

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  2 in total

1.  Natural history of Fabry disease in affected males and obligate carrier females.

Authors:  K D MacDermot; A Holmes; A H Miners
Journal:  J Inherit Metab Dis       Date:  2001       Impact factor: 4.982

2.  Differential assay for lysosomal alpha-galactosidases in human tissues and its application to Fabry's disease.

Authors:  J S Mayes; J B Scheerer; R N Sifers; M L Donaldson
Journal:  Clin Chim Acta       Date:  1981-05-05       Impact factor: 3.786

  2 in total
  5 in total

1.  Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A (IVS4+919G>A).

Authors:  Wuh-Liang Hwu; Yin-Hsiu Chien; Ni-Chung Lee; Shu-Chuan Chiang; Robert Dobrovolny; Ai-Chu Huang; Hui-Ying Yeh; May-Chin Chao; Shio-Jean Lin; Teruo Kitagawa; Robert J Desnick; Li-Wen Hsu
Journal:  Hum Mutat       Date:  2009-10       Impact factor: 4.878

2.  Non-invasive high-risk screening for Fabry disease hemizygotes and heterozygotes.

Authors:  Teruo Kitagawa; Ken Suzuki; Nobuyuki Ishige; Toya Ohashi; Masahisa Kobayashi; Yoshikatsu Eto; Akemi Tanaka; Hideo Odaka; Misao Owada
Journal:  Pediatr Nephrol       Date:  2008-06-06       Impact factor: 3.714

Review 3.  Fabry's disease: an example of cardiorenal syndrome type 5.

Authors:  Aashish Sharma; Marco Sartori; Jose J Zaragoza; Gianluca Villa; Renhua Lu; Elena Faggiana; Alessandra Brocca; Luca Di Lullo; Sandro Feriozzi; Claudio Ronco
Journal:  Heart Fail Rev       Date:  2015-11       Impact factor: 4.214

Review 4.  Fabry disease.

Authors:  Dominique P Germain
Journal:  Orphanet J Rare Dis       Date:  2010-11-22       Impact factor: 4.123

5.  A prospective, observational study of patients with uncommon distal symmetric painful small-fiber neuropathy.

Authors:  Jung-Lung Hsu; Ming-Feng Liao; Hui-Ching Hsu; Yi-Ching Weng; Ai-Lun Lo; Kuo-Hsuan Chang; Hong-Shiu Chang; Hung-Chou Kuo; Chin-Chang Huang; Long-Sun Ro
Journal:  PLoS One       Date:  2017-09-28       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.